JP2024540220A - Ｄｓｇ２組成物及び方法 - Google Patents

Ｄｓｇ２組成物及び方法 Download PDF

Info

Publication number
JP2024540220A
JP2024540220A JP2024525855A JP2024525855A JP2024540220A JP 2024540220 A JP2024540220 A JP 2024540220A JP 2024525855 A JP2024525855 A JP 2024525855A JP 2024525855 A JP2024525855 A JP 2024525855A JP 2024540220 A JP2024540220 A JP 2024540220A
Authority
JP
Japan
Prior art keywords
dsg2
protein
seq
isolated polypeptide
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024525855A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540220A5 (enExample
Inventor
イン フー、シー
エドワード タイラー、ライアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arvada Therapeutics Inc
Original Assignee
Arvada Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arvada Therapeutics Inc filed Critical Arvada Therapeutics Inc
Publication of JP2024540220A publication Critical patent/JP2024540220A/ja
Publication of JP2024540220A5 publication Critical patent/JP2024540220A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2024525855A 2021-11-02 2022-11-02 Ｄｓｇ２組成物及び方法 Pending JP2024540220A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163274707P 2021-11-02 2021-11-02
US63/274,707 2021-11-02
PCT/US2022/079106 WO2023081674A1 (en) 2021-11-02 2022-11-02 Dsg2 compositions and methods

Publications (2)

Publication Number Publication Date
JP2024540220A true JP2024540220A (ja) 2024-10-31
JP2024540220A5 JP2024540220A5 (enExample) 2025-11-11

Family

ID=84569745

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024525855A Pending JP2024540220A (ja) 2021-11-02 2022-11-02 Ｄｓｇ２組成物及び方法

Country Status (12)

Country Link
US (1) US20240279304A1 (enExample)
EP (1) EP4426430A1 (enExample)
JP (1) JP2024540220A (enExample)
KR (1) KR20240110819A (enExample)
CN (1) CN118369351A (enExample)
AR (1) AR127555A1 (enExample)
AU (1) AU2022382972A1 (enExample)
CA (1) CA3236070A1 (enExample)
IL (1) IL312219A (enExample)
MX (1) MX2024005327A (enExample)
TW (1) TW202334190A (enExample)
WO (1) WO2023081674A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117860721A (zh) * 2023-12-25 2024-04-12 五邑大学 三甲基氯化铵在制备冠状病毒刺突蛋白受体结合结构域的特异性结合剂中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965197A (en) 1987-06-12 1990-10-23 Massachusetts Institute Of Technology Coryneform expression and secretion system
KR100316347B1 (ko) 1998-09-15 2002-08-27 한미약품(주) 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법
DE10057397A1 (de) 2000-11-18 2002-05-23 Hella Kg Hueck & Co Vorrichtung zur Ölstandsmessung
DK2147104T3 (en) 2007-05-21 2015-12-14 Danisco Us Inc USING A ASPARAGINPROTEASE- (NSP24) SIGNAL SEQUENCE FOR heterologous protein EXPRESSION
US8324578B2 (en) 2008-09-30 2012-12-04 Apple Inc. Hidden sensors in an electronic device
KR101410845B1 (ko) 2009-09-10 2014-06-23 바이오콘 리미티드 새로운 프로리파제-보바인 트립시노겐 융합 단백질
JP2012107935A (ja) * 2010-11-16 2012-06-07 Mitsubishi Chemicals Corp Ｄｅｓｍｏｇｌｅｉｎ−２蛋白質による脳梗塞の検査方法
RU2632651C2 (ru) 2011-05-11 2017-10-06 Чилдрен'С Медикал Сентер Корпорейшн Модифицированный биотин-связывающий белок, слитые белки на его основе и их применение
EP3568697B1 (en) * 2017-01-13 2022-06-29 The Hospital for Sick Children Method for diagnosis of arrhythmogenic right ventricular cardiomyopathy
CA3202364A1 (en) * 2020-12-15 2022-06-23 Arvada Therapeutics, Inc. Dsg2 compositions and methods for the treatment of covid-19

Also Published As

Publication number Publication date
MX2024005327A (es) 2024-05-21
KR20240110819A (ko) 2024-07-16
EP4426430A1 (en) 2024-09-11
TW202334190A (zh) 2023-09-01
CA3236070A1 (en) 2023-05-11
AR127555A1 (es) 2024-02-07
WO2023081674A1 (en) 2023-05-11
AU2022382972A1 (en) 2024-05-09
US20240279304A1 (en) 2024-08-22
CN118369351A (zh) 2024-07-19
IL312219A (en) 2024-06-01

Similar Documents

Publication Publication Date Title
JP7856872B2 (ja) 組織石灰化の治療方法
US20180112193A1 (en) Csf1 therapeutics
JP7005019B2 (ja) 組織修復のための二重特異性治療用タンパク質
JP6825181B2 (ja) 膵炎を治療するための薬剤の製造におけるｉｌ−２２二量体の使用
US10034915B2 (en) Small heat shock proteins and active fragments thereof as a therapy for inflammation and ischemia
ES2796743T3 (es) Un polipéptido de receptor de factor de crecimiento de fibroblastos 3 (FGR3) soluble para su uso en la prevención o tratamiento de trastornos de retraso del crecimiento esquelético
JP2020509011A (ja) エリスロポエチン由来ペプチドの細胞損傷防止に対する効果を介した活用
CN119548617B (zh) 重组xvii型人源化胶原蛋白的新用途
US20240279304A1 (en) Dsg2 compositions and methods
JP2024500250A (ja) Ｃｏｖｉｄ－１９の治療のためのｄｓｇ２組成物及び方法
US20240043495A1 (en) Dsg2 compositions and methods for the treatment of covid-19
JP2025069136A (ja) 線維性疾患の治療のための抗エフリン－ｂ２遮断抗体
JP6416480B2 (ja) 関節リウマチまたはその関連疾患の予防または治療剤
CN116648255A (zh) 用于治疗covid-19的dsg2组合物和方法
JP7016125B2 (ja) 脳梗塞の治療薬
WO2022020544A1 (en) Method of treating an inflammatory condition
HK40049107B (en) Activin receptor type iia variants and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251031

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251031